SG10201701942VA - Producer cells for replication competent retroviral vectors - Google Patents
Producer cells for replication competent retroviral vectorsInfo
- Publication number
- SG10201701942VA SG10201701942VA SG10201701942VA SG10201701942VA SG10201701942VA SG 10201701942V A SG10201701942V A SG 10201701942VA SG 10201701942V A SG10201701942V A SG 10201701942VA SG 10201701942V A SG10201701942V A SG 10201701942VA SG 10201701942V A SG10201701942V A SG 10201701942VA
- Authority
- SG
- Singapore
- Prior art keywords
- retroviral vectors
- producer cells
- replication competent
- competent retroviral
- replication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21806309P | 2009-06-17 | 2009-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201701942VA true SG10201701942VA (en) | 2017-05-30 |
Family
ID=43357050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701942VA SG10201701942VA (en) | 2009-06-17 | 2010-06-17 | Producer cells for replication competent retroviral vectors |
| SG2011093416A SG176890A1 (en) | 2009-06-17 | 2010-06-17 | Producer cells for replication competent retroviral vectors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011093416A SG176890A1 (en) | 2009-06-17 | 2010-06-17 | Producer cells for replication competent retroviral vectors |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10316333B2 (en) |
| EP (3) | EP3546583A1 (en) |
| JP (3) | JP5923037B2 (en) |
| CN (2) | CN107129971A (en) |
| CA (1) | CA2764107A1 (en) |
| DK (2) | DK3159415T3 (en) |
| ES (2) | ES2609336T3 (en) |
| IL (2) | IL216799A (en) |
| SG (2) | SG10201701942VA (en) |
| WO (1) | WO2010148203A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| EP2346995B1 (en) * | 2008-09-26 | 2018-11-07 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| EP3546583A1 (en) * | 2009-06-17 | 2019-10-02 | Tocagen Inc. | Producer cells for replication competent retroviral vectors |
| US9663834B2 (en) | 2010-07-16 | 2017-05-30 | Tocagen Inc. | Retrovirus detection |
| CA2849045C (en) * | 2011-09-29 | 2020-11-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vectors pseudotyped with mutant baev glycoproteins |
| US11065311B2 (en) | 2012-10-25 | 2021-07-20 | Denovo Biopharma Llc | Retroviral vector with mini-promoter cassette |
| JP2016526920A (en) * | 2013-08-05 | 2016-09-08 | トカジェン インコーポレーテッド | Recombinant vector with optimized A-bulge |
| CN103667350B (en) * | 2013-12-12 | 2015-10-21 | 杭州电子科技大学 | A kind of carrier system and method changing retrovirus incasing cell preferendum |
| ES2779149T3 (en) | 2014-03-26 | 2020-08-13 | Tocagen Inc | Retroviral vector that has immunostimulatory activity |
| WO2015168102A2 (en) * | 2014-04-28 | 2015-11-05 | Board Of Regents, The University Of Texas System | Prolonged protein stabilization by resveratrol |
| KR20180048743A (en) * | 2015-09-04 | 2018-05-10 | 토카겐 인크. | 2A < / RTI > peptide. |
| SG11201810871WA (en) * | 2016-07-25 | 2019-01-30 | Us Health | Methods of producing modified natural killer cells and methods of use |
| GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| EP3784278A4 (en) * | 2018-04-27 | 2021-07-07 | Mayo Foundation for Medical Education and Research | Foamy viruses and methods of use |
| WO2020102437A1 (en) * | 2018-11-13 | 2020-05-22 | Tocagen Inc. | Recombinant vectors comprising genes for binding domains and secretable peptides |
| TW202120551A (en) | 2019-08-12 | 2021-06-01 | 美商普瑞諾生物科技公司 | Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells |
| WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| TW202332694A (en) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | Serum half-life extended pd-l1 binding polypeptides |
| TW202334196A (en) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 binding polypeptides |
| CN114360743B (en) * | 2022-03-16 | 2022-05-17 | 普瑞基准生物医药(苏州)有限公司 | Differential transcription expression profile after drug action and prediction method of drug indications |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| JP2897295B2 (en) * | 1989-12-14 | 1999-05-31 | 味の素株式会社 | DNA construct for high production of retrovirus and cell line for high production of retrovirus |
| CA2092195C (en) * | 1990-09-21 | 2000-04-18 | Douglas J. Jolly | Retroviral packaging cell line |
| AU7971194A (en) | 1993-10-12 | 1995-05-04 | Chiron Corporation | Methods for preserving recombinant viruses |
| AU729986B2 (en) | 1997-10-25 | 2001-02-22 | Roche Diagnostics Gmbh | Suspension packaging cell lines for retroviral vectors |
| US6451304B1 (en) | 1998-03-09 | 2002-09-17 | The Regents Of The University Of California | Method for retrovirus vector production by separated gag and pol expression |
| CA2346931C (en) | 1998-10-01 | 2011-11-29 | University Of Southern California | Gene delivery system and methods of use |
| US6899871B2 (en) * | 1998-10-01 | 2005-05-31 | University Of Southern California | Gene delivery system and methods of use |
| US6576463B1 (en) | 1999-01-15 | 2003-06-10 | The Regents Of The University Of California | Hybrid vectors for gene therapy |
| EP1161549A2 (en) | 1999-03-15 | 2001-12-12 | Chiron Corporation | Retrovirus producing cells utilizing a high multiplicity of transduction |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| EP1468099A2 (en) * | 2002-01-17 | 2004-10-20 | Lonza Biologics plc | Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
| WO2004007753A2 (en) * | 2002-07-17 | 2004-01-22 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements |
| EP1697505A1 (en) | 2003-12-23 | 2006-09-06 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
| WO2005116225A1 (en) | 2004-05-25 | 2005-12-08 | Children's Hospital Medical Center | Method for introducing and expressing rna in cells |
| US9057056B2 (en) | 2004-09-29 | 2015-06-16 | Takara Bio Inc. | Method for producing retrovirus using human producer cells with increased N-acetylglucosaminyltransferase III activity |
| WO2006058231A2 (en) | 2004-11-24 | 2006-06-01 | Nanovector Limited | Viral vectors |
| CN102076215A (en) | 2008-06-30 | 2011-05-25 | 托卡根公司 | Formulations of 5-fluorocytosine and uses thereof |
| EP2346995B1 (en) | 2008-09-26 | 2018-11-07 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| EP3546583A1 (en) * | 2009-06-17 | 2019-10-02 | Tocagen Inc. | Producer cells for replication competent retroviral vectors |
| US9663834B2 (en) | 2010-07-16 | 2017-05-30 | Tocagen Inc. | Retrovirus detection |
| WO2012058673A2 (en) | 2010-10-31 | 2012-05-03 | Tocagen Inc. | Enhanced cancer treatment and monitoring using recombinant vectors |
| US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
-
2010
- 2010-06-17 EP EP19156480.6A patent/EP3546583A1/en not_active Withdrawn
- 2010-06-17 CN CN201710168480.6A patent/CN107129971A/en active Pending
- 2010-06-17 EP EP16191371.0A patent/EP3159415B1/en not_active Not-in-force
- 2010-06-17 DK DK16191371.0T patent/DK3159415T3/en active
- 2010-06-17 SG SG10201701942VA patent/SG10201701942VA/en unknown
- 2010-06-17 CN CN2010800323544A patent/CN102459616A/en active Pending
- 2010-06-17 WO PCT/US2010/038996 patent/WO2010148203A2/en active Application Filing
- 2010-06-17 DK DK10790193.6T patent/DK2443242T3/en active
- 2010-06-17 US US13/376,827 patent/US10316333B2/en active Active
- 2010-06-17 JP JP2012516300A patent/JP5923037B2/en active Active
- 2010-06-17 CA CA2764107A patent/CA2764107A1/en not_active Abandoned
- 2010-06-17 SG SG2011093416A patent/SG176890A1/en unknown
- 2010-06-17 ES ES10790193.6T patent/ES2609336T3/en active Active
- 2010-06-17 ES ES16191371T patent/ES2718546T3/en active Active
- 2010-06-17 EP EP10790193.6A patent/EP2443242B1/en not_active Not-in-force
-
2011
- 2011-12-06 IL IL216799A patent/IL216799A/en not_active IP Right Cessation
-
2015
- 2015-12-24 JP JP2015251391A patent/JP6335869B2/en active Active
-
2017
- 2017-08-23 IL IL254118A patent/IL254118B/en not_active IP Right Cessation
-
2018
- 2018-05-01 JP JP2018087936A patent/JP6609663B2/en active Active
-
2019
- 2019-06-04 US US16/431,626 patent/US11060112B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20120087894A1 (en) | 2012-04-12 |
| JP2016105711A (en) | 2016-06-16 |
| IL254118B (en) | 2019-06-30 |
| EP2443242A4 (en) | 2012-11-14 |
| EP3546583A1 (en) | 2019-10-02 |
| US10316333B2 (en) | 2019-06-11 |
| WO2010148203A2 (en) | 2010-12-23 |
| EP3159415B1 (en) | 2019-03-13 |
| IL216799A (en) | 2017-09-28 |
| CN107129971A (en) | 2017-09-05 |
| EP2443242A2 (en) | 2012-04-25 |
| IL216799A0 (en) | 2012-02-29 |
| JP2012530495A (en) | 2012-12-06 |
| JP5923037B2 (en) | 2016-05-24 |
| IL254118A0 (en) | 2017-10-31 |
| US20190352667A1 (en) | 2019-11-21 |
| JP6335869B2 (en) | 2018-05-30 |
| SG176890A1 (en) | 2012-01-30 |
| US11060112B2 (en) | 2021-07-13 |
| JP6609663B2 (en) | 2019-11-20 |
| EP2443242B1 (en) | 2016-10-26 |
| ES2718546T3 (en) | 2019-07-02 |
| ES2609336T3 (en) | 2017-04-19 |
| DK3159415T3 (en) | 2019-04-23 |
| WO2010148203A3 (en) | 2011-08-25 |
| CA2764107A1 (en) | 2010-12-23 |
| JP2018139602A (en) | 2018-09-13 |
| DK2443242T3 (en) | 2017-01-30 |
| CN102459616A (en) | 2012-05-16 |
| EP3159415A1 (en) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216799A0 (en) | Producer cells for replication competent retroviral vectors | |
| HK1249547A1 (en) | Fucosylation-deficient cells | |
| EP2463931A4 (en) | Packaging material for electrochemical cells | |
| GB0908613D0 (en) | T Cell Reseptors | |
| ZA201300244B (en) | Hydrogen membrane separator | |
| EP2403046A4 (en) | Solid sulfide electrolyte material | |
| EP2433953A4 (en) | Cell membrane-permeable peptides | |
| ZA201109522B (en) | T cell receptors | |
| EP2471128A4 (en) | Release system for electrochemical cells | |
| EP2476655A4 (en) | Sulfide solid electrolyte | |
| HK1138687A1 (en) | Fast cell search | |
| GB0914195D0 (en) | Vessel for culturing cells | |
| EP2641966A4 (en) | Vitrificated storage solution for cells | |
| EP2426769A4 (en) | Reformer for fuel cell | |
| GB0913469D0 (en) | Cell support | |
| IL221575A (en) | Cells for providing angiogenesis | |
| HK1165764A1 (en) | Folder for storage | |
| GB0920775D0 (en) | Cells | |
| PL2223739T3 (en) | Steam reformer | |
| PT2405924E (en) | Plasma-adapted full electrolyte solution | |
| HK1149924A1 (en) | Hydrogen storage materials | |
| EP2489633A4 (en) | Hydrogen storage material | |
| GB0917143D0 (en) | Cell stack | |
| GB0908839D0 (en) | Storage/separating material | |
| PL2406174T3 (en) | Cartridge for the generation of hydrogen |